ARA-290 is a peptide that is a variation of erythropoietin (EPO). Research has shown to increase the generation of red blood cells and decrease the activity of inflammatory pathways, but can it also be an immune system booster? According to findings from many scientific studies, the ARA 290 peptide is effective in reducing HbA1c levels, bringing down blood pressure, enhancing cholesterol levels, promoting wound healing, and providing neuroprotective benefits.
The following paragraphs will present extensive information on ARA-290, including its research and effects. You may purchase ARA-290 straight from Core Peptides if you click here in case you are a researcher interested in examining this peptide for its implications on treatment. Please scroll down to get further information on the ARA 290 peptide.
What exactly is the ARA 290?
Peptide ARA 290, derived from EPO, is now the subject of research to see whether it can improve cell survival, control blood pressure, and stimulate blood vessel development, among other potential advantages.
Studies have shown that this glycoprotein also has a pain-relieving effect and neuroprotective properties. The ARA-290 phase II clinical studies are now over, and the peptide will soon be moving on to the phase III clinical trials to understand further how it affects diabetes.
ARA 290 Peptide Research
The Maintenance and Defense of Tissues
Studies show that therapy with ARA-290 inhibits macrophage activation, which, according to research conducted on mice, improves the health of islet cells [i] in the body and ensures their continued life. Compared to exogenous insulin, the control that islet cells give over blood sugar is superior, which reduces the number of problems. The study on ARA-290 demonstrates that this peptide may increase the time that islet cells can survive after transplantation. However, these cells do not survive transplantation for an extended period.
In addition, research shows that ARA 290 peptide protects against typical inflammatory reactions and enhances tissue protection. Consequently, this leads to accelerated wound healing, accelerated repair, and decreased mortality, as shown by studies conducted on animals.
Avoiding the Spread of Disease
According to studies conducted on mice, administering ARA 290 increases the length of time cells can survive and makes it possible for endothelial colony-forming cells (ECFCs) to construct and mend damaged blood arteries in the body. Preventing retinal ischemia, the primary cause of blindness in industrialized countries, is another benefit of preserving these cells, as per research.
More recent research suggests that the ARA 290 peptide improves the migration, proliferation, and overall health of ECFCs while simultaneously targeting parts of the vasculature that need repair.
Immune System Booster
The results of recent clinical studies suggest that ARA-290 may be able to assist in improving research subjects’ immune systems.
To provide a concise explanation, the tissue-protective receptor, also known as TPR, is expressed in various immune cells, including dendritic cells, macrophages, mast cells, and lymphocytes.
According to the findings of several scientific studies, ARA-290 can bind to the TPR found in immune cells and directly affect the functioning of those cells. When ARA 290 promotes TPR, it significantly decreases the creation of proinflammatory cytokines such as IL-6. As a result, the severity of illnesses is mitigated, and new diseases are prevented from developing in the first place.
Pain Relief
Studies have shown that targeting the innate repair receptor may decrease inflammation and neuropathic pain. This aspect is even though neuropathic pain is notoriously difficult to treat. It has been shown, via research conducted on animals, that the administration of ARA-290 can act on the IRR and suppress TRPV1 activity. The ARA 290 peptide, which treats the pain associated with multiple sclerosis, diabetes, and amputation, works by acting on this receptor. Researchers showed this result via studies conducted on animals.
Research shows that the treatment with ARA-290 therapy may also increase the number of tiny nerve fibers [ii], typically associated with certain autoimmune illnesses. This process can result in a considerable reduction in the amount of pain experienced. As a result of a study conducted on animals, many scientists have concluded that ARA-290 might be a helpful therapy for nerve damage caused by illnesses such as diabetes, celiac disease, thyroid disease, and HIV.
References
[i] Heij, Lara, Marieke Niesters, Maarten Swartjes, Elske Hoitsma, Marjolein Drent, Ann Dunne, Jan C. Grutters, et al. “Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study.” Molecular Medicine 18, no. 11 (November 2012): 1430–1436. doi:10.2119/molmed.2012.00332.
[ii] Dahan, Albert, Ann Dunne, Maarten Swartjes, Paolo L. Proto, Lara Heij, Oscar Vogels, Monique van Velzen, et al. “Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density.” Molecular Medicine 22, no. 1 (January 2016): 674–674. doi:10.2119/molmed.2013.00122.erratum.
